Design and synthesis of novel anti-Alzheimer's agents: Acridine-chromenone and quinoline-chromenone hybrids

Bioorganic Chemistry

Volumn 67, Issue , 2016, Pages 84-94

  Najafi, Zahra ^a   Saeedi, Mina ^a,b   Mahdavi, Mohammad ^c   Sabourian, Reyhaneh ^b   Khanavi, Mahnaz ^a   Tehrani, Maliheh Barazandeh ^a   Moghadam, Farshad Homayouni ^d   Edraki, Najmeh ^e   Karimpor Razkenari, Elahe ^b   Sharifzadeh, Mohammad ^a   Foroumadi, Alireza ^b   Shafiee, Abbas ^b   Akbarzadeh, Tahmineh ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acridine chromenone; Alzheimer's disease; Anti cholinesterase; Docking study; Neuroprotective activity; Quinoline chromenone; Secretase inhibitor

Indexed keywords

4 METHYL 7 [4 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 4 METHYL 7 [4 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 4 METHYL 7 [4 [(7 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 4 METHYL 7 [4 [(7,8,9,10 TETRAHYDRO 6H CYCLOPENTA[B]QUINOLIN 11 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 (2 CHLORO 7,8,9,10 TETRAHYDRO 6H CYCLOPENTA[B]QUINOLIN 11 YLAMINO)PHENOXY] 4 METHYL 2H CHROMEN 2 ONE; 7 [4 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 4 METHYL 2H CHROMEN 2 ONE; 7 [4 [(3 CHLORO 7,8,9,10 TETRAHYDRO 6H CYCLOPENTA[B]QUINOLIN 11 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(3 CHLORO 7,8,9,10 TETRAHYDRO 6H CYCLOPENTA[B]QUINOLIN 11 YL)AMINO]PHENOXY] 4 METHYL 2H CHROMEN 2 ONE; 7 [4 [(6 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(6 CHLORO 2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(6 CHLORO 2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 4 METHYL 2H CHROMEN 2 ONE; 7 [4 [(7 CHLORO 1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(7 CHLORO 2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; 7 [4 [(7 CHLORO 2,3 DIHYDRO 1H CYCLOPENTA[B]QUINOLIN 9 YL)AMINO]PHENOXY] 4 METHYL 2H CHROMEN 2 ONE; 7 [4 [(7,8,9,10 TETRAHYDRO 6H CYCLOPENTA[B]QUINOLIN 11 YL)AMINO]PHENOXY] 2H CHROMEN 2 ONE; ACETYLCHOLINESTERASE; ACRIDINE DERIVATIVE; BETA SECRETASE; CHOLINESTERASE INHIBITOR; CHROMENE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; QUINOLINE DERIVATIVE; RIVASTIGMINE; UNCLASSIFIED DRUG; CHOLINESTERASE; CHROMONE DERIVATIVE; QUINOLINE;

ARTICLE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR WEIGHT; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE AREA; ALZHEIMER DISEASE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; PC12 CELL LINE; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACRIDINES; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PC12 CELLS; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84975502614     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2016.06.001     Document Type: Article

References (43)

1. V.J. De-Paula, M. Radanovic, B.S. Diniz, and O.V. Forlenza Alzheimer's disease Subcell. Biochem. 65 2012 329 352
2. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 2014 27 50
3. V.N. Talesa Acetylcholinesterase in Alzheimer's disease Mech. Ageing Dev. 122 2001 1961 1969
4. P.T. Francis, A.M. Palmer, M. Snape, and G.K. Wilcock The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psych. 66 1999 137 147
5. J. Massoulie, L. Pezzementi, S. Bon, E. Krejci, and F.M. Vallette Molecular and cellular biology of cholinesterases Prog. Neurobiol. 41 1993 31 91
6. R.M. Lane, S.G. Potkin, and A. Enz Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int. J. Neuropsychopharmacol. 9 2006 101 124
7. N.H. Greig, T. Utsuki, Q. Yu, X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, and D.K. Lahiri A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase Curr. Med. Res. Opin. 17 2001 159 165
8. I.R. Macdonald, K. Rockwood, E. Martin, and S. Darvesh Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? J. Alzheimers. Dis. 42 2014 379 384
9. F. Rahim, M. Tariq Javed, H. Ullah, A. Wadood, M. Taha, M. Ashraf, Qurat-ul-Ain, M. Anas Khan, F. Khan, S. Mirza, and K.M. Khan Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease Bioorg. Chem. 62 2015 106 116
10. P. Meena, V. Nemaysh, M. Khatri, A. Manral, P.M. Luthra, and M. Tiwari Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease Bioorg. Med. Chem. 23 2015 1135 1148
11. N. Edraki, O. Firuzi, A. Foroumadi, R. Miri, A. Madadkar-Sobhani, M. Khoshneviszadeh, and A. Shafiee Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors of b-secretase (BACE1) Bioorg. Med. Chem. 21 2013 2396 2412
12. A. Gella, and N. Durany Oxidative stress in Alzheimer disease Cell Adhes. Migr. 3 2009 88 93
13. F.M. Longo, and S.M. Massa Neuroprotective strategies in Alzheimer's disease NeuroRx 1 2004 117 127
14. H. Dvir, I. Silman, M. Harel, T.L. Rosenberry, and J.L. Sussman Acetylcholinesterase: from 3D structure to function Chem. Biol. Interact. 18 2010 10 22
15. A. Castro, and A. Martinez Peripheral and dual binding site acetylcholinesterase inhibitors: implications in the treatment of Alzheimer's disease Mini Rev. Med. Chem. 1 2001 267 272
16. Y.P. Li, F.X. Ning, M. Bi, Y.C. Yang, M.H. Li, T.M. Nie, and J.H.Tan. Ou Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation Eur. J. Med. Chem. 46 2011 1572 1581
17. M. Rosini, V. Andrisano, M. Bartolini, M.L. Bolognesi, P. Hrelia, A. Minarini, A. Tarozzi, and C. Melchiorre Rational approach to discover multipotent anti-Alzheimer drugs J. Med. Chem. 48 2005 360 363
18. M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. Bolognesi, A. Minarini, V. Tumiatti, V. Andrisano, I.R. Mellor, and C. Melchiorre Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 51 2008 4381 4384
19. P.B. Watkins, H.J. Zimmerman, M.J. Knapp, S.I. Gracon, and K.W. Lewis Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease JAMA. 271 1994 992 998
20. M.L. Crismon Tacrine: first drug approved for Alzheimer's disease Ann. Pharmacother. 28 1994 744 751
21. L. Fang, B. Kraus, J. Lehmann, J. Heilmann, Y. Zhang, and M. Decker Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates Bioorg. Med. Chem. Lett. 18 2008 2905 2909
22. S. Senapati, Y. Cheng, and J.A. McCammon In-situ synthesis of a tacrine-triazole-based inhibitor of acetylcholinesterase: configurational selection imposed by steric interactions J. Med. Chem. 49 2006 6222 6230
23. P. Munoz-Ruiz, L. Rubio, E. GarcÍa-Palomero, I. Dorronsoro, M. Del Monte-Millán, R. Valenzuela, P. Usán, C. De Austria, M. Bartolini, V. Andrisano, A. Bidon-Chanal, M. Orozco, F.J. Luque, M. Medina, and A. MartÍnez Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease J. Med. Chem. 48 2005 7223 7233
24. P. Anand, B. Singh, and N. Singh A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease Bioorg. Med. Chem. 20 2012 1175 1180
25. S. Hamulakova, L. Janovec, M. Hrabinova, K. Spilovska, J. Korabecny, P. Kristian, K. Kuca, and J. Imrich Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors J. Med. Chem. 57 2014 7073 7084
26. S.-S. Xie, X.-B. Wang, J.-Y. Li, L. Yang, and L.-Y. Kong Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease Eur. J. Med. Chem. 64 2013 540 553
27. Q. Sun, D.Y. Peng, S.G. Yang, X.L. Zhu, W.C. Yang, and G.F. Yang Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Ab aggregation, and β-secretase Bioorg. Med. Chem. 22 2014 4784 4791
28. M. Khoobi, M. Alipour, A. Moradi, A. Sakhteman, H. Nadri, S.F. Razavi, M. Ghandi, A. Foroumadi, and A. Shafiee Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3′,4′:5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase Eur. J. Med. Chem. 68 2013 291 300
29. M. Mohammadi-Khanaposhtani, M. Mahdavi, M. Saeedi, R. Sabourian, M. Safavi, M. Khanavi, A. Foroumadi, A. Shafiee, and T. Akbarzadeh Design, synthesis, biological evaluation, and docking study of acetylcholinesterase inhibitors: new acridone-1,2,4-oxadiazole-1,2,3-triazole hybrids Chem. Biol. Drug Des. 86 2015 1425 1432
30. M. Mohammadi-Khanaposhtani, M. Saeedi, N.S. Zafarghandi, M. Mahdavi, R. Sabourian, E.K. Razkenari, H. Alinezhad, M. Khanavi, A. Shafiee, A. Foroumadi, and T. Akbarzadeh Potent acetylcholinesterase inhibitors: design, synthesis, biological evaluation, and docking study of acridone linked to 1,2,3-triazole derivatives Eur. J. Med. Chem. 92 2015 799 806
31. M. Saeedi, S. Ansari, M. Mahdavi, R. Sabourian, T. Abarzadeh, A. Foroumadi, and A. Shafiee Synthesis of novel 1,2,3-triazole-dihydro[3,2-c]chromenones as acetylcholinesterase inhibitors Synth. Commun. 45 2015 2311 2318
32. A. Rayatzadeh, M. Saeedi, M. Mahdavi, Z. Rezaei, R. Sabourian, M.H. Mosslemin, T. Akbarzadeh, A. Foroumadi, and A. Shafiee Synthesis and evaluation of novel oxoisoindolines derivatives as acetylcholinesterase inhibitors Monatsh. Chem. 146 2015 637 643
33. M.K. Hu, and C.F. Lu A facile synthesis of bis-tacrine isosteres Tetrahedron Lett. 41 2000 1815 1818
34. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-Stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 71 1961 88 95
35. M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. Bolognesi, A. Minarini, V. Tumiatti, V. Andrisano, I.R. Mellor, and C. Melchiorre Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 51 2008 4381 4384
36. P. Camps, X. Formosa, C. Galdeano, D. Muñoz-Torrero, L. Ramírez, E. Gómez, N. Isambert, R. Lavilla, A. Badia, M.V. Clos, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodríguez-Franco, O. Huertas, T. Dafni, and F.J. Luque Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase and β-amyloid-directed anti-alzheimer compounds J. Med. Chem. 52 2009 5365 5379
37. J. Gordon, S. Amini, and M.K. White General overview of neuronal cell culture Meth. Mol. Biol. 1078 2013 1 8
38. E. Tamango, P. Bardini, A. Obbili, A. Vitali, R. Borghi, D.J. Zaccheo, D. Zaccheo, M.A. Pronzato, O. Danni, M.A. Smith, G. Perry, and M. Tabaton Oxidative stress increases expression and activity of BACE in NT2 neurons Neurobiol. Dis. 10 2002 279 288
39. N. Yassa, H. Razavi Beni, and A. Hadjiakhoondi Free radical scavenging and lipid peroxidation activity of the Shahani black grap Pak. J. Biol. Sci. 11 2008 2513 2516
40. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
41. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Meth. 44 2000 235 249
42. M. Bulut, and C. Erk Improved synthesis of some hydroxycoumarins Dyes Pigm. 30 1996 99 104
43. M. Khoobi, F. Ghanoni, H. Nadri, A. Moradi, M. Pirali Hamedani, F. Homayouni Moghadam, S. Emami, M. Vosooghi, R. Zadmard, A. Foroumadi, and A. Shafiee New tetracyclic tacrine analogs containing pyrano[2,3-c]pyrazole: efficient synthesis, biological assessment and docking simulation study Eur. J. Med. Chem. 89 2015 296 303